CLAIMS

1. ~~An~~ Use of an isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, in the manufacture of a medicament for treating or preventing asthma in a human subject wherein, when administered intravenously to the human ~~a~~ subject at a dose of about 0.3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting:

(a) an area under the curve (AUC) of between about 1,500 and about 2,700 μgh/ml;

(b) a volume of distribution of between about 65 and 125 mL/kg;

(c) a peak concentration (C_{max}) of between about 5 and about 8 μg/ml; and

(d) a clearance rate of between about 0.1 and about 0.2 ml/h/kg.

2. Use of an isolated composition comprising about 0.3 mg/kg of an anti-IL-13 antibody, or antigen-binding portion thereof, in the manufacture of a medicament for treating asthma in a human subject, wherein the composition is formulated for intravenous administration, and wherein the antibody, or antigen-binding portion thereof, is capable of exhibiting at least one pharmacokinetic characteristic selected from the group consisting of:

(a) a clearance rate of between about 0.11 to about 0.19 mL/hr/kg; or

(b) a volume of distribution of between about 70 to about 130 mL/kg.

~~2. An isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, wherein, when administered intravenously to a subject at a dose of about 3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting:~~

~~(a) an area under the curve (AUC) of between about 21,000 and about 33,500 μgh/ml;~~

~~(b) a volume of distribution of between about 55 and about 100 mL/kg;~~

~~(c) a peak concentration (C_{max}) of between about 55 and about 90 μg/ml; and~~

~~(d) a clearance rate of between about 0.08 and about 0.15 ml/h/kg.~~

~~3. An isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, wherein, when administered intravenously to a subject at a dose~~

of about 10 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting:

(a) an area under the curve (AUC) of between about 75 and about 100 μgh/ml;

(b) a volume of distribution of between about 90 and about130 mL/kg;

(c) a peak concentration (C_{max}) of between about 185 and about 250 μg/ml; and

(d) a clearance rate of between about 0.1 and about 0.15 ml/h/kg.

4. An isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 0.3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting:

(a) an area under the curve (AUC) of between about 125 and about 800 μgh/ml; and

(b) a peak concentration (C_{max}) of between about 1.0 and about 6.0 μg/ml.

5. An isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting:

(a) an area under the curve (AUC) of between about 1,100 and about 8,500 μgh/ml; and

(b) a peak concentration (C_{max}) of between about 12 and about 60 μg/ml.

~~6~~3. The ~~composition~~ use of ~~any one of~~ claims ~~1-5~~ or claim 2, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is 13C5.5, or an antigen-binding portion thereof.

~~7~~4. The ~~composition~~ use of ~~any one of~~ claims ~~1-5~~ or claim 2, wherein the composition is a pharmaceutical composition.

~~8. A method of treating or preventing asthma in a subject comprising administering the composition of any one of claims 1-5 to the subject, thereby treating or preventing asthma in said subject.~~

~~9~~5. The ~~method~~ use of claim ~~8~~1 or claim 2, wherein the composition is formulated for administration~~administered~~ once.

~~10~~6. The ~~method~~ use of claim ~~8~~1 or claim 2, wherein the composition is formulated for administration~~administered~~ weekly.

~~11~~7. The ~~method~~ use of claim ~~10~~ 1 or claim 2, wherein the composition is formulated for administration~~administered~~ for about 3 weeks.

~~12~~8. The ~~method~~ use of claim ~~8~~1 or claim 2, wherein the asthma is mild to moderate asthma.

~~13~~9. The ~~method~~ use of claim ~~8~~1 or claim 2, further comprising ~~administering~~ an additional agent ~~to said subject~~.

~~14~~10. The ~~method~~ use of claim ~~13~~9, wherein said additional agent is selected from the group consisting of: a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof; methotrexate, a cyclosporin, a rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an anti-rheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an oral steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

~~15. A method of treating asthma in a subject comprising intravenously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, wherein at least one pharmacokinetic characteristic selected from the group consisting of:~~

~~(a) a maximum serum concentration (C_{max}) of between about 5 and about 235 µg/mL, and~~

~~(b) an area under the serum concentration-time curve (AUC) of between about 1,500 and about 98,000 µgh/mL,~~

~~is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.~~

~~16. The method of claim 15, wherein the antibody, or antigen-binding portion thereof, is administered at a dose of about 0.3 mg/kg.~~

17. The method of claim 16, wherein the C_{max} is between about 5 and about 10 μg/mL.

18. The method of claim 16, wherein the AUC is between about 1,500 and about 2,700 μgh/mL.

19. The method of claim 15, wherein the antibody, or antigen-binding portion thereof, is administered at a dose of about 3 mg/kg.

20. The method of claim 19, wherein the C_{max} is between about 55 and about 90 μg/mL.

21. The method of claim 19, wherein the AUC is between about 20,000 and about 34,000 μgh/mL.

22. The method of claim 15, wherein the antibody, or antigen-binding portion thereof, is administered at a dose of about 10 mg/kg.

23. The method of claim 22, wherein the C_{max} is between about 190 and about 235 μg/mL.

24. The method of claim 22, wherein the AUC is between about 75,000 and about 100,000 μgh/mL.

25. The method of claim 15, wherein the C_{max} value is between about 20 and about 30 (μg/mL)/(mg/kg) after dose normalization.

26. The method of claim 15, wherein the AUC is between about 6,000 and about 10,000 (μgh/mL)/(mg/kg) after dose normalization.

27. A method of treating asthma in a subject comprising subcutaneously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

(a) a maximum serum concentration (C_{max}) of between about 1 and about 60 μg/mL, and

(b) an area under the serum concentration-time curve (AUC) of between about 125 and about 8,100 μgh/mL,

is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.

28. The method of claim 27, wherein the antibody, or antigen-binding portion thereof, is administered at a dose of about 0.3 mg/kg.

29. The method of claim 28, wherein the C_{max} is between about 1 and about 6 μg/mL.

30. The method of claim 28, wherein the AUC is between about 100 and about 800 μgh/mL.

31. The method of claim 27, wherein the antibody, or antigen-binding portion thereof, is administered at a dose of about 3 mg/kg.

32. The method of claim 31, wherein the C_{max} is between about 12 and about 60 μg/mL.

33. The method of claim 31, wherein the AUC is between about 1,100 and about 8,100 μgh/mL.

34. The method of any one of claims 15 or 27, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is 13C5.5, or an antigen-binding portion thereof.

35. The method of any one of claims 15 or 27, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is administered once.

36. The method of any one of claims 15 or 27, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is administered weekly.

37. The method of claim 36, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is administered for three weeks.

38. The method of any one of claims 15 or 27, wherein said asthma is mild to moderate asthma.

39. The method of any one of claims 15 or 27, further comprising the administration of an additional agent.

40. The method of claim 39, wherein said additional agent is selected from the group consisting of: a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof; methotrexate, a cyclosporin, a rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an anti-rheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an oral steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

41. A method of treating asthma in a subject comprising subcutaneously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

(a) a half-life of between about 24 and 31 days;

(b) a T_{max} of between about 3 and about 5 days; and

(c) a bioavailability of at least about 60%

is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.

42. The method of claim 41, wherein the bioavailability is at least about 70%.

43. A method of treating asthma in a subject comprising subcutaneously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, at a dose of about 3 mg/kg, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

(a) a half-life of between about 23 and 26 days;

(b) a T_{max} of less than or equal to about 5 days; and

(c) a bioavailability of at least about 60%

is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.

44. The method of claim 43, wherein the bioavailability is at least about 70%.

45. A method of treating asthma in a subject comprising intravenously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

(a) a clearance rate of between about 0.11 to about 0.19 mL/hr/kg; and

(b) a volume of distribution of between about 70 to about 130 mL/kg

is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.

46. A method of treating asthma in a subject comprising intravenously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof,

at a dose of about 3 mg/kg, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

(a) a clearance rate of between about 0.08 to about 0.14 mL/hr/kg; and

(b) a volume of distribution of between about 55 to about 100 mL/kg

is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.

47. A method of treating asthma in a subject comprising intravenously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, at a dose of about 10 mg/kg, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

(a) a clearance rate of between about 0.09 to about 0.13 mL/hr/kg; and

(b) a volume of distribution of between about 85 to about 130 mL/kg

is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.

48. The method of any one of claims 41-47, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is 13C5.5, or an antigen-binding portion thereof.

49. The method of any one of claims 41-47, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is administered once.

50. The method of any one of claims 41-47, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is administered weekly.

51. The method of claim 50, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is administered for 3 weeks.

52. The method of any one of claims 41-47, wherein said asthma is mild to moderate asthma.

53. The method of any one of claims 41-47, further comprising administering an additional agent to said subject.

54. The method of claim 53, wherein said additional agent is selected from the group consisting of: a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof; methotrexate, a cyclosporin, a rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an anti-rheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an oral steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

55. The composition of any one of claims 1-5 or the method of any one of claims 15, 27, 41, 43 or 45-47, wherein said subject is a human.

56. An isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, wherein, when administered intravenously to a subject at a dose

of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting any of the pharmacokinetic parameters set forth in the specification, Tables or Figures.

57. An isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg or 3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting any of the pharmacokinetic parameters set forth in the specification, Tables or Figures.

58. A method of treating or preventing asthma in a subject comprising intravenously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg, wherein at least one of the pharmacokinetic characteristics set forth in the specification, Tables or Figures is achieved following administration of the antibody, or antigen-binding portion thereof, to said subject.

59. A method of treating or preventing asthma in a subject comprising subcutaneously administering to the subject an anti-IL-13 antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg, wherein at least one of the pharmacokinetic characteristics set forth in the specification, Tables or Figures is achieved following administration of the antibody, or antigen-binding portion thereof, to said subject.